Login Register Cart 0
Generic placeholder image

Recent Advances in Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-4344
ISSN (Online): 2772-4352

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Perspective

New Frontier in Antiviral Drugs for Disorders of the Respiratory System

Author(s): Hai-Long Zhang*, Yong-Xia Li, Ai-Feng Zhou and Yiqian Li

Volume 17, Issue 1, 2022

Published on: 22 July, 2022

Page: [2 - 12] Pages: 11

DOI: 10.2174/1574891X16666220416164740

Abstract

Background: COVID-19 is still soaring, and the new delta COVID-19 variant is on the rise and spreading around the world.

Objective: We conducted a patent analysis to better understand the therapeutic strategy developed for antivirals available for the disorders of the respiratory system.

Materials and Methods: European granted patents filed from January 2002 to June 2021 were analyzed. We used a combination of International patent classification (IPC) “A61p31/12” and “A61p11/00” to search the relevant documents.

Results: Our study showed R&D of antiviral drugs for disorders of the respiratory system to be decreasing over the past 20 years. Chemical drugs showed various chemical structures. The development of chemical drugs or herbal medicines appeared to commence earlier than the biological products. Also, the results indicated that large global companies play a leading role in developing kinase inhibitors as chemical drugs.

Conclusion: There are three strategies for developing antiviral drugs for the disorders of the respiratory system, including chemical drugs, herbal medicines or natural products, and biological products. Herbal medicines may provide a new insight and approach to developing antiviral drugs for disorders of the respiratory system. A combination of chemical drugs and natural products may be a promising therapeutic method for treating patients with COVID- 19.

Keywords: Antiviral drugs, patent, therapeutic strategy, COVID-19, kinase inhibitors, herbal medicines.

« Previous Next »
[1]
World Health Organization. WHO Coronavirus (COVID- 19) Dashboard. Available from: https://covid19.who.int/
[2]
World Health Organization. Available from: https://covid19.who.int/region/searo/country/in
[3]
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384(5): 403-16.
[http://dx.doi.org/10.1056/NEJMoa2035389] [PMID: 33378609]
[4]
Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. N Engl J Med 2021; 384(23): 2187-201.
[http://dx.doi.org/10.1056/NEJMoa2101544] [PMID: 33882225]
[5]
Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): An exploratory analysis of a randomised controlled trial. Lancet 2021; 397(10282): 1351-62.
[http://dx.doi.org/10.1016/S0140-6736(21)00628-0] [PMID: 33798499]
[6]
Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021; 384(15): 1412-23.
[http://dx.doi.org/10.1056/NEJMoa2101765] [PMID: 33626250]
[7]
Pyrimidylpyrrole derivatives active as kinase inhibitors. Patent EP1660475B1, 2004.
[8]
Pyridylpyrrole derivatives active as kinase inhibitors. Patent EP1660085B1 2004.
[9]
Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents. Patent EP06120487A2, 2002.
[10]
Amino-benzimidazoles derivatives as inhibitors of respiratory syncytial virus replication. Patent EP1711485B1, 2004.
[11]
Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication. Patent EP1723136B1 2004.
[12]
5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication. Patent EP1697347B1 2004.
[13]
Derivatives of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics. Patent EP1537096B1 2003.
[14]
Indole derivatives and their use as ligands for cb2 receptors. Patent EP1507758B1 2003.
[15]
Amino-phthalazinone derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them. Patent DK1427708T3, 2002.
[16]
Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof. Patent EP1526860B1 2003.
[17]
The isoflavone derivatives of tectoridin, the preparation thereof and the Anti-virus medicines containing the same as the effective constituents. Patent EP1630160B1, 2004.
[18]
Medicinal composition for treating respiratory infectious diseases. Patent EP2008710603, 2014.
[19]
Recombinant IL-9 antibodies & uses thereof. Patent EP2316487B1, 2004.
[20]
Short bioactive peptides and methods for their use. Patent EP2009159563, 2002.
[21]
Recombinant il-9 antibodies and uses thereof. Patent EP1613273B1 2004.
[22]
Oxazolyl-pyrazole derivatives as kinase inhibitors. Patent EP1377589B1, 2002.
[23]
Tricyclic n-heteroaryl-carboxamide derivatives, preparation thereof and therapeutic use of same. Patent EP2185558B1 2008.
[24]
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various autoimmune diseases. Patent EP2650007B1, 2009.
[25]
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases. Patent EP2489361B1 2009.
[26]
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases. Patent EP2296684B1, 2009.
[27]
(1s, 2s, 3s, 4r)-3-ý(1S)-1-acetylamino-2-ethyl-butyl¨- 4-guanidino-2- hydroxyl-cyclopentyl-1-carboxylic acid hydrates and pharmaceutical uses thereof. Patent EP2186795B1 2008.
[28]
Zhang H-L, Li Y. Recent trend for egfr-based and alk-based targets: A patent analysis. Recent Patents Anticancer Drug Discov 2021; 16(3): 298-311.
[http://dx.doi.org/10.2174/1574892816666210413151906] [PMID: 33847258]
[29]
Zhang H-L, Zhou A-F, Li Y. Patent Insight into the Development of Therapeutic Strategies against Coronaviruses. Open COVID J 2021; 1(1): 93-100.
[http://dx.doi.org/10.2174/2666958702101010093]
[30]
Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based hetero-logous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021; 397(10275): 671-81.
[http://dx.doi.org/10.1016/S0140-6736(21)00234-8] [PMID: 33545094]
[31]
Pormohammad A, Zarei M, Ghorbani S, et al. Efficacy and safety of covid-19 vaccines: A systematic review and me-ta-analysis of randomized clinical trials. Vaccines (Basel) 2021; 9(5): 467.
[http://dx.doi.org/10.3390/vaccines9050467] [PMID: 34066475]
[32]
Chu L, McPhee R, Huang W, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and im-munogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine 2021; 39(20): 2791-9.
[http://dx.doi.org/10.1016/j.vaccine.2021.02.007] [PMID: 33707061]
[33]
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397(10269): 99-111.
[http://dx.doi.org/10.1016/S0140-6736(20)32661-1] [PMID: 33306989]
[34]
Wang WY, Xie Y, Zhou H, Liu L. Contribution of traditional Chinese medicine to the treatment of COVID-19. Phytomedicine 2021; 85: 153279.
[http://dx.doi.org/10.1016/j.phymed.2020.153279] [PMID: 32675044]
[35]
Nile SH, Kai G. Recent clinical trials on natural products and traditional chinese medicine combating the COVID-19. Indian J Microbiol 2020; 61(1): 1-6.
[http://dx.doi.org/10.1007/s12088-020-00919-x] [PMID: 33390627]
[36]
Tuta-Quintero EA, Suárez-Ramirez V, Pimentel J. Efficacy and safety of traditional Chinese medicine in COVID-19: A scoping review. Rev Int Acupunt 2020; 14(4): 132-50.
[http://dx.doi.org/10.1016/j.acu.2020.09.001]
[37]
Li JG, Xu H. Chinese medicine in fighting against covid-19: Role and inspiration. Chin J Integr Med 2021; 27(1): 3-6.
[http://dx.doi.org/10.1007/s11655-020-2860-x] [PMID: 33420601]
[38]
Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res 2007; 74(2): 92-101.
[http://dx.doi.org/10.1016/j.antiviral.2006.04.014] [PMID: 16730806]
[39]
Elfiky AA. Natural products may interfere with SARS-CoV-2 attachment to the host cell. J Biomol Struct Dyn 2021; 39(9): 3194-203.
[http://dx.doi.org/10.1080/07391102.2020.1761881] [PMID: 32340551]
[40]
Gyebi GA, Ogunro OB, Adegunloye AP, Ogunyemi OM, Afolabi SO. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CLpro): An in silico screening of alkaloids and terpenoids from African medicinal plants. J Biomol Struct Dyn 2021; 39(9): 3396-408.
[http://dx.doi.org/10.1080/07391102.2020.1764868] [PMID: 32367767]
[41]
Abd El-Aziz NM, Eldin Awad OM, Shehata MG, El-Sohaimy SA. Inhibition of the SARS-CoV-2 RNA-Dependent RNA polymerase by natural bioactive compounds: Molecular docking analysis. Egypt J Chem 2021; 64(4): 1989-2001.
[http://dx.doi.org/10.21608/ejchem.2021.45739.2947]
[42]
Goswami D, Kumar M, Ghosh SK, Das A. Natural product compounds in alpinia officinarum and ginger are potent SARS-CoV-2 papain-like protease inhibitors. ChemRxiv 2020.
[http://dx.doi.org/10.26434/chemrxiv.12071997.v1]
[43]
Kumar V, Dhanjal JK, Bhargava P, et al. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells. J Biomol Struct Dyn 2020.
[http://dx.doi.org/10.1080/07391102.2020.1775704] [PMID: 32469279]
[44]
Yu MS, Lee J, Lee JM, et al. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coro-navirus helicase, nsP13. Bioorg Med Chem Lett 2012; 22(12): 4049-54.
[http://dx.doi.org/10.1016/j.bmcl.2012.04.081] [PMID: 22578462]
[45]
Chen CN, Lin CPC, Huang KK, et al. Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3,3′- digallate (TF3). Evid Based Complement Alternat Med 2005; 2(2): 209-15.
[http://dx.doi.org/10.1093/ecam/neh081] [PMID: 15937562]
[46]
Michelini FM, Alché LE, Bueno CA. Virucidal, antiviral and immunomodulatory activities of β-escin and Aesculus hip-pocastanum extract. J Pharm Pharmacol 2018; 70(11): 1561-71.
[http://dx.doi.org/10.1111/jphp.13002] [PMID: 30168142]
[47]
The United States Food and Drug Administration Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021902s000_approv.pdf
[48]
The United States Food and Drug Administration Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202292s000lbl.pdf
[49]
The Heads of Medicines Agencies Available from: https://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_46_work-sharing/Sativex_2018_09.pdf

Rights & Permissions Print Cite
Article Metrics
23
2
© 2024 Bentham Science Publishers | Privacy Policy